By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
List view / Grid view
Filter the results
A new protein-based nanoparticle vaccine protected mice against a variety of coronaviruses, researchers have shown.
Researchers will use the in vitro model to study how respiratory viruses, like SARS-CoV-2, cause Acute Respiratory Distress Syndrome (ARDS) and develop potential interventions.
Researchers show that genomic tracking can be used to trace individual virus transmission lineages and could therefore be adopted for future pandemics.
A new analysis suggests SARS-CoV-2-specific antibodies remain relatively stable for eight months and Spike protein-specific memory B cells increase in number over time.
A new study suggests that inflammation and blood vessel damage may be the primary causes of neurological symptoms in COVID-19 patients, instead of the virus infecting the brain.
According to researchers, an interaction between host microRNA and SARS-CoV-2 could be responsible for the range of disease severities.
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Scientists have created a prognostic classification model which uses biomarkers to help predict an individual’s risk of developing severe COVID-19 symptoms.
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Scientists report their phage-based inhaled vaccine delivery system elicited a robust antibody response in both mice and non-human primates.
Scientists shows targeting cholesterol or phosphatidylinositol phosphate (PIP) could be a promising strategy to combat multiple coronaviruses.
Two new studies suggest that SARS-CoV-2-specific IgA antibodies are more neutralising and therefore COVID-19 vaccines should encourage an IgA response.
Study suggests reducing the expression of the methyl-CpG-binding domain 2 (MBD2) protein on macrophages could be a viable therapeutic strategy for lung fibrosis.